1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,410 | 1,470 | 12:43 | |
| 1,410 | 1,480 | 20.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.11. | NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | 439 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September... ► Artikel lesen | |
| 04.11. | NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am | 598 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 22.10. | NanoViricides President Dr. Diwan to Present at the PODD Conference | 314 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 15.10. | NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology | 482 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 14.10. | NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy | 2 | Insider Monkey | ||
| 08.10. | InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) to Discuss Its 'Trojan Horse' Platform Technology at Upcoming Global AMR Summit | 1 | iNVEZZ.com | ||
| 08.10. | NanoViricides to Present at the Global AMR Summit 2024 Tomorrow | 457 | ACCESSWIRE | Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides... ► Artikel lesen | |
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | 457 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30... ► Artikel lesen | |
| 27.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 26.09. | NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs | 600 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that... ► Artikel lesen | |
| 26.08. | MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX | 594 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it... ► Artikel lesen | |
| 19.08. | NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections | 891 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 09.08. | NanoViricides extends executive contracts, grants stock | 1 | Investing.com | ||
| 09.08. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics | 575 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 01.08. | "NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides | 692 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate... ► Artikel lesen | |
| 24.07. | COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides | 717 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today reminds the strong... ► Artikel lesen | |
| 11.07. | A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides | 627 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development... ► Artikel lesen | |
| 24.06. | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides | 622 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 51,30 | +0,59 % | XETR MODIFICATIONS OF SHARE INDICES EFFECTIVE 23 DECEMBER 2024 | For the following instruments, the Product Assignment Group in Xetra (MIC: XETR) will change with effect from 23 December 2024:Instrument Mnemonic ISIN Product Assignment Group (old) Product Assignment... ► Artikel lesen | |
| GAUZY | 9,650 | +12,60 % | GAUZY LTD: Gauzy Receives Outstanding Supplier Award for Its Smart-Vision Advanced Driver Assistance System (ADAS) From World's Largest Commercial Bus Manufacturer, Yutong | ||
| ONTO INNOVATION | 161,00 | 0,00 % | Oppenheimer Reaffirms "Outperform" Rating for Onto Innovation (NYSE:ONTO) | ||
| VEECO INSTRUMENTS | 26,200 | +1,55 % | PlayNitride qualifies Veeco's Lumina MOCVD system for micro-LED production | ||
| XTPL | 21,800 | -6,24 % | EQS-News: XTPL S.A.: XTPL raises PLN 27.6 m in the series X share offering to scale up its commercial sales to PLN 100 m | Issuer: XTPL S.A.
/ Key word(s): Capital Increase/Financing
XTPL raises PLN 27.6 m in the series X share offering to scale up its commercial sales to PLN 100 m
06.12.2024... ► Artikel lesen | |
| KOPIN | 1,270 | +3,08 % | Kopin Aktie: Starke Wachstumsimpulse entdeckt! | Die Kopin Corporation, ein führender Entwickler von Nano-Halbleitern, verzeichnet aktuell eine beachtliche Marktentwicklung. Der Aktienkurs des Technologieunternehmens konnte im letzten Monat einen... ► Artikel lesen | |
| ZENTEK | 0,860 | +4,88 % | Zentek Provides Update on International Opportunities | GUELPH, ON / ACCESSWIRE / December 12, 2024 / Zentek Ltd. (" Zentek "or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, has signed a Memorandum... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,117 | +4,46 % | FendX Technologies Inc.: FendX Announces RSU Grant | Oakville, Ontario--(Newsfile Corp. - December 19, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection... ► Artikel lesen | |
| DOTZ NANO | 0,059 | +5,41 % | DOTZ NANO LIMITED: Strategic Collaboration Agreement with Bar-Ilan University | ||
| GOMSPACE | 0,440 | -6,18 % | GomSpace Group AB: GomSpace returns to comprehensive market guidance with strong outlook for 2025 | The company is indicating a year-on-year revenue growth of more than 30%, strong EBITDA improvement, and positive free cashflow for full year 2025. The company will deliver positive free cashflow for... ► Artikel lesen | |
| NANOFOCUS | 1,240 | 0,00 % | NanoFocus passt Prognose für 2024 an | Die NanoFocus AG hat heute beschlossen, die Prognose für das laufende Jahr anzupassen. Aufgrund von gegenwärtig absehbar deutlich niedrigeren Umsätzen in den Bereichen Semiconductor Asia und Standard/Labor... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,460 | +1,32 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| ACACIA RESEARCH | 4,060 | 0,00 % | Acacia Research Reports Third Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today... ► Artikel lesen | |
| LEHNER INVESTMENTS | 0,022 | 0,00 % | EQS-News: LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Personalie
LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand
25.11.2024 / 16:15 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| RIBER | 2,680 | 0,00 % | RIBER: Solid Business Growth at End-September 2024 | SOLID BUSINESS GROWTH AT END-SEPTEMBER 2024 Revenues up +14% to €18.5mOrder book strengthened to €38.3m (+14%) Bezons, October 30, 2024 - 8:00am - RIBER, the global leader for molecular beam epitaxy... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell -2,78 % bei einem Aktienkurs von 1,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.
